Company news
Oncolytics Biotech Inc. news in 2022
Oncolytics Biotech Inc.'s news releases, calls and decks from 2022, newest first.
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
November 30, 2022
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium
November 20, 2022
Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
November 6, 2022
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
October 4, 2022
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors
September 7, 2022
Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
August 11, 2022
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
July 27, 2022
Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET
June 28, 2022
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
June 17, 2022
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference
May 10, 2022
Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights
May 5, 2022
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
May 4, 2022
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
May 2, 2022
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
April 28, 2022
Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 21, 2022
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine
April 14, 2022
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference
April 12, 2022
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting
April 8, 2022
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting
April 8, 2022
Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress
April 6, 2022
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
March 31, 2022
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
March 24, 2022
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
March 17, 2022
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
March 9, 2022
Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting
March 9, 2022
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
March 3, 2022
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
February 2, 2022
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
January 27, 2022
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 20, 2022
Oncolytics Biotech® Releases a Letter to Shareholders - 2021 Review and 2022 Outlook
January 11, 2022
Calls in 2022
- Oncolytics Biotech (NASDAQ:ONCY) Q3 2022 Earnings Call
Nov 7, 2022
Transcript - Oncolytics Biotech (NASDAQ:ONCY) Q2 2022 Earnings Call
Aug 11, 2022
Transcript - Oncolytics Biotech (NASDAQ:ONCY) Q1 2022 Earnings Call
May 5, 2022
Transcript - Oncolytics Biotech (NASDAQ:ONCY) Q4 2021 Earnings Call
Mar 3, 2022
Transcript